Find out more about how the Apax Funds partnered with Neuraxpharm to create a leading European specialty pharmaceutical companyNeuraxpharm
Specialty pharmaceutical company focused on the treatment of central nervous system disorders
Neuraxpharm is a leading European specialty pharmaceutical company focused on the treatment of central nervous system disorders (CNS). With over 100 CNS molecules, the company offers a wide range of effective, differentiated and affordable CNS treatment options to patients, healthcare professionals and industry partners. Neuraxpharm has a direct presence in all major European countries including Germany, Spain, Italy, France, the UK and Poland and plans further geographic expansion in the near term as part of its strategy to strengthen its position as a European CNS leader. The company also manufactures pharmaceutical forms and active pharmaceutical ingredients indicated for the CNS and respiratory areas with an international presence in more than 50 countries. Consolidated as a group in 2016 and backed by Funds advised by Apax Partners, Neuraxpharm has a unique understanding of the CNS market based on over 30 years’ of experience.